Equities research analysts at StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a research note issued on Saturday. The brokerage set a “hold” rating on the stock.
Separately, HC Wainwright decreased their price objective on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, August 12th.
Read Our Latest Stock Analysis on ONCT
Oncternal Therapeutics Stock Performance
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.14. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. The company had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $0.24 million. During the same quarter in the previous year, the company posted ($3.00) earnings per share. On average, analysts predict that Oncternal Therapeutics will post -11.63 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Oncternal Therapeutics stock. Quantum Private Wealth LLC acquired a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned approximately 0.94% of Oncternal Therapeutics at the end of the most recent reporting period. 16.05% of the stock is owned by institutional investors and hedge funds.
Oncternal Therapeutics Company Profile
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
See Also
- Five stocks we like better than Oncternal Therapeutics
- Why is the Ex-Dividend Date Significant to Investors?
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- Which Wall Street Analysts are the Most Accurate?
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.